The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Yakusheva E.V.

Academy of Postgraduate Education of the Federal Research and Clinical Center

Dukhanin A.S.

Pirogov Russian National Research Medical University

Iskra D.A.

Saint Petersburg State Pediatric Medical University

Naumov A.V.

Pirogov Russian National Research Medical University;
Russian Gerontological Research and Clinical Center

Runikhina N.K.

Russian Gerontological Research and Clinical Center

Strakhov M.A.

N.I. Pirogov Russian National Research Medical University

Personalized patient-oriented approach to the treatment of musculoskeletal pain syndrome using over-the-counter medications. Resolution of the Expert Council (May 28, 2023)

Authors:

Yakusheva E.V., Dukhanin A.S., Iskra D.A., Naumov A.V., Runikhina N.K., Strakhov M.A.

More about the authors

Read: 989 times


To cite this article:

Yakusheva EV, Dukhanin AS, Iskra DA, Naumov AV, Runikhina NK, Strakhov MA. Personalized patient-oriented approach to the treatment of musculoskeletal pain syndrome using over-the-counter medications. Resolution of the Expert Council (May 28, 2023). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):134‑138. (In Russ.)
https://doi.org/10.17116/jnevro2023123081134

References:

  1. Danilov AnB, Shugurova IM. Topical forms of NSAIDs from the perspective of evidence-based medicine. Manage Pain. 2023;2:28-36. (In Russ).
  2. Naumov AV, Vorobyeva NM, Khovasova NO, et al. The prevalence of osteoarthritis and its association with geriatric syndromes in people over 65: data from the Russian epidemiological study EVKALIPT. Terapevticheskii Arkhiv. 2021;93(12):1482-1490. (In Russ.). https://doi.org/10.26442/00403660.2021.12.201268
  3. Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33(3):529-545.  https://doi.org/10.1007/s40520-020-01762-2
  4. Global Health Group Data Exchange. Accessed: Nov 15, 2022. https://ghdx.healthdata.org/gbd-results-tool
  5. Taylor RS, Fotopoulos G, Maibach H. Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions. Cur Med Res Opin. 2011;27(3):605-622.  https://doi.org/10.1185/03007995.2010.550606
  6. Karateev AE, Lila AM. Osteoarthritis: a modern clinical concept and some promising therapeutic approaches. Scientific and Practical Rheumatology. 2018;56(1):70-81. (In Russ.).
  7. Osteoarthritis Guideline. ACR, 2019  https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Osteoarthritis
  8. Choi E, Nahm FS, Han WK, et al. Topical agents: a thoughtful choice for multimodal analgesia. Korean J Anesthesiol. 2020 Oct;73(5):384-393.  https://doi.org/10.4097/kja.20357
  9. Shi C, et al. Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain. J Clin Med. 2023;12(4):1544. https://doi.org/10.3390/jcm12041544
  10. OARSI Guidelines 2019. https://www.sciencedirect.com/science/article/pii/S1063458419311161
  11. Bruyere O. A consensus statement of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) algorithm for the management of knee osteoarthritis — From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4 suppl):3-11.  https://doi.org/10.1016/j.semarthrit.2015.11.010
  12. Trame MN. Systems pharmacology to predict drug safety in drug development. Eur J Pharm Sci. 2016;94:93-95.  https://doi.org/10.1016/j.ejps.2016.05.027
  13. Hagen M, Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017;33:1623-1634. https://doi.org/10.1080/03007995.2017.1352497
  14. Chanturia AV, Vismont FI, Stepanova NA, et al. Pathological physiology. Minsk: Vysh. school: textbook;. 2016. (In Russ.).
  15. Jett MF, Ramesha CS, Brown CD, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther. 1999;288(3):1288-1297.
  16. Kokate A, Li X, Jasti B. Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical Note. AAPS PharmSciTech. 2008;9(2):501-504.  https://doi.org/10.1208/s12249-008-9071-7
  17. Instructions for medical use of the drug Voltaren Emulgel 1%. РУ П N016030/01, 09.09.2009. (In Russ.).
  18. Instructions for medical use of the drug Voltaren Emulgel 2%. РУ ЛП-002267, 04.10.13. (In Russ.).
  19. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81-110.  https://doi.org/10.18433/J3T886
  20. Wade AG, Crawford GM, Young D. Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries. J Int Med Res. 2019;47(9):4454-4468. https://doi.org/10.1177/0300060519859146
  21. Badokin VV. The effect of non-steroidal anti-inflammatory drugs on the metabolism of articular cartilage. RMJ. 2013;32:1657. (In Russ).
  22. Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000;131(7):1413-1421. https://doi.org/10.1038/sj.bjp.0703710
  23. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Delivery. 2016;23(2):564-578.  https://doi.org/10.3109/10717544.2014.935532
  24. Zolnay PA. Ex vivo comparative study between absorption and storage through the skin of Diclofenac 2.32% gel and Diclofenac 5% gel. Mozgásszervi Továbbképző Szemle. 2021;4(1):12-18. 
  25. Kohan H, Gilzad A. In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%). Int J Pharm Compd. 2021;25(2):146-155. 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.